VYCO (Vycor Medical) Interest Expense : $-0.10 Mil (TTM As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vycor Medical's interest expense for the three months ended in Sep. 2024 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vycor Medical's Operating Income for the three months ended in Sep. 2024 was $ -0.04 Mil. Vycor Medical's Interest Expense for the three months ended in Sep. 2024 was $ -0.03 Mil. Vycor Medical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vycor Medical Interest Expense Historical Data

The historical data trend for Vycor Medical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vycor Medical Interest Expense Chart

Vycor Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.07

-0.08

-0.09

-0.10

Vycor Medical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.03	-0.03	-0.03	-0.03	-0.03

Vycor Medical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

Vycor Medical (OTCPK:VYCO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vycor Medical's Interest Expense for the three months ended in Sep. 2024 was $-0.03 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-0.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.21 Mil.

Vycor Medical's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Vycor Medical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Vycor Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487

Website

https://www.vycormedical.com

Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.

Executives

David Cantor	director, officer: President	1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell	director, officer: Chairman	ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou	director, 10 percent owner, officer: Chief Executive Officer	C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush	director	C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti	director	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd	10 percent owner	PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical Headlines

From GuruFocus

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2018

By ACCESSWIRE AccessWire • 04-12-2019

Vycor Medical Reports Financial Results for the year ended December 31st, 2019

By Marketwired Marketwired • 03-27-2020

Treatment for blindness successful in largest ever study

By Marketwired Marketwired • 02-26-2020

Vycor Value Could be Unlocked with These Major Partnerships

By Last Financier Last Financier • 12-05-2014

New Study Shows Vision Rehab Treatment Effective for Stroke and Injury Related Blindness

By Marketwired Marketwired • 02-27-2020

Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement

By Marketwired Marketwired • 06-30-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2017

By ACCESSWIRE AccessWire • 04-12-2019